Introduction {#sec1-1}
============

*Prameha* vis-à-vis diabetes mellitus (DM)\[[@ref1][@ref2]\] has been described in all classical texts of Ayurveda. The etymology, etiology, pathogenesis, clinical features, complications, prognosis and treatment of this disease are described in an extremely rational perspective. The concept of DM as known in conventional western medicine would reveal that this disease was fairly well-known even in the classical period of Ayurveda.\[[@ref3][@ref4][@ref5]\]

The role of genetic and hereditary factors as described in the context of *Sahaja Prameha* (simulating juvenile type-1 diabetes) and the role of high-calorie diet and sedentary habits have been described as the sheet anchors of *Madhumeha* diathesis. This idea seems to be amazingly contemporary. Similarly, the description of two types of diabetes under the terms, (1) *Krisha Pramehi*, that is, thin diabetic and (2) *Sthula Pramehi*, that is, obese diabetic warranting distinctly different lines of management in Ayurveda again appears quite similar to the classification of diabetes as type-1 and type-2 in modern medicine suggesting the quality treatment modalities.\[[@ref6][@ref7]\]

The Ayurvedic texts describe the prodromal features and characteristic symptoms of *Prameha/Madhumeha* with great clarity and objectivity. The texts also deliberate on the prognosis of this disease putting emphasis on the fact that this disease is difficult to treat. Several complications, including neuropathy, angiopathy, uropathy, retinopathy and proneness to infections, including the formation of carbuncles have been described with their diagnosis and treatment in Ayurvedic classics.\[[@ref8]\]

Ayurveda largely involves *Nidana Parivarjana*, that is, elimination of the cause, dietary restrictions and exercise besides a range of herbal and herbo-mineral formulations for the treatment of different kinds of diabetes. Most of the Ayurvedic texts suggest that diabetic diathesis could be categorized into *Kaphaja* (10 types), *Pittaja* (6 types) and *Vataja* (4 types) *Prameha*. The Ayurvedic dietetics, lifestyle management including *Sadvritta* and *Achara* (code of conduct) are emphasized.

The Ayurvedic texts describe *Silajatu* as a *Naimittika Rasayana* for *Prameha* and hence it is advisable to use *Silajatu* in prediabetics and/or in diabetic management as an adjuvant therapy for promotive and preventive measure.\[[@ref9][@ref10]\] Classically *Silajatu* is well known for its *Naimittika Rasayana* effect, *Ojovardhaka* and *Pramehaghna* property. Dalhana\'s commentary on Sushruta considered *Silajatu* as the best *Naimittika Rasayana* (Adjuvant therapy) for *Prameha*.\[[@ref11]\]

With this perspective the present study aims to undertake a clinical evaluation of two important Ayurvedic *Naimittika Rasayana* drugs namely (1) *Mamajjaka* (*Enicostemma littorale* Blume.) and (2) *Silajatu* (*Asphaltum punjabinum*) in cases of type-2 diabetes mellitus (DM-2).

Materials and Methods {#sec1-2}
=====================

Selection of patients {#sec2-1}
---------------------

A series of patients of either sex of DM-2 were screened from OPD and IPD of Institute of Medical Sciences, BHU, Varanasi. The study was approved by the institutional ethics committee (IEC). Informed consent was obtained from all patients before their recruitment for this study. Most of the patients were already known diabetics, but few were diagnosed for the first time when they came with some other complaints.

Inclusion criteria {#sec2-2}
------------------

Patients having classical symptoms of diabetes and unequivocal blood sugar elevation checked twicePatients between age groups of 30 and 65 yearsIncreased fasting blood sugar (FBS) \>126 mg/dl more than two occasionsIncreased postprandial blood sugar (PPBS) \>200 mg/dlCut-off blood sugar: Fasting is 200 mg/dl and PPBS is 300 mg/dlNon-control of blood sugar in spite of adequate doses of oral hypoglycemic drugs such as any single drug of Sulfonylureas group for the adequate duration on the prescription of a diabetologist.

Exclusion criteria {#sec2-3}
------------------

Patients of DM-1 or juvenile onset diabetesPatients \<30 years and \>65 yearsPatients of DM-2 on insulin therapyDiabetes with severe complications such as tuberculosis other pyogenic infection, blindness, stroke, etcPregnant and lactating mothersPatients with recurrent infectionsPatients under corticosteroid therapy.

Grouping and pososlogy {#sec2-4}
----------------------

A total of 95 patients of DM were registered for the present study. These patients were randomly allocated into three groups based on computer-generated random allocation sequence. Of 95 patients, 84 patients turned up for full follow-up.

Group A: DM-2 patients who were not taking any oral hypoglycemic drug and patients with uncontrolled DM-2 who were already taking oral hypoglycemic drug. Cap. *Mamajjaka* (500 mg) twice a day with water after meal was administered for three monthsGroup B: DM-2 patients who were not taking any oral hypoglycemic drug and patients with uncontrolled DM-2 who were already taking oral hypoglycemic drug. Cap. *Silajatu* (500 mg) twice a day with water after meal was administered for three monthsGroup C (Control Group): DM-2 patients who were already taking oral hypoglycemic drug on a prescription. The ongoing conventional modern treatment prescribed by Diabetologist allowed to continue witout any other additional intervention.

### Procurement of the trial drugs {#sec3-1}

The total aqueous extract of *Mamajjaka* (whole plant *E. littorale*) was procured from Ansar Industries, Surat (Gujarat) and was filled in capsules of 500 mg without any excipient. Standard *Suddha Silajatu* was procured from Dabur India and was used in 500 mg capsules twice daily. The Dabur *Silajatu* (having fulvic acid as marker compound 3.45 mg/capsule) is a product purified with *Triphala Kwatha* standardized as per Ayurvedic Pharmacopoeia of India standard and marketed by Dabur, India.

Dosage, duration and follow-up {#sec2-5}
------------------------------

The prepared 500 mg *Mamajjaka* extract capsules and *Silajatu* 500 mg capsules were administered with water in a dose of one capsule twice daily, after a meal for 3 months. The patients were allowed to continue on the diet, which they were already taking. No additional dietary or life style restrictions were prescribed to eliminate nondrug response, although most of the patients were already on a controlled diet for long time. Diabetic patients who were diagnosed first time were also not enforced any additional dietary restrictions during the trial and were treated with the trial drugs as above and response of treatment was assessed at monthly intervals for 3 months.

Criteria for assessment {#sec2-6}
-----------------------

The patients were assessed for clinical symptoms and physical findings using a symptom rating scale besides estimation of blood sugar and glycosylated Hb%, *Ojas* and *Agni* status in each follow-ups during the trial period with the help of *Agni* and *Ojas* rating scales.\[[@ref12][@ref13]\]

### Clinical parameters {#sec3-2}

Assessment of drug response was done in terms of grade scores (0--3) of clinical symptoms of Diabetes such as polyuria, polydipsia, weakness, polyphagia, joint pain cramps on walking, loss of libido and sensory neuropathic symptoms such as tingling sensation, hyperesthesia, numbness, hot/cold sensation, burning sensation and pain (especially in lower limbs) and status of *Ojas* and *Agni* by using the rating scales designed\[[@ref14]\] for this purpose which are prepared on the basis of Ayurvedic classics as described in Sushruta Samhita,\[[@ref15]\] and Charaka Samhita.\[[@ref16]\] These scales have been designed on the basis of degree of severity of a particular clinical feature grading into 0, 1, 2, 3. For example, *Bala* (physical strength) is one of the fourteen functions of *Ojas* which was qualitatively categorized as below:

0 = Can perform excessive work without fatigue

1 = Can carry out routine activity without getting fatigue

2 = Performs routine activity with fatigue

3 = Difficulty to perform or cannot perform routine activity.

Pain was measured by the VAS (grade score 0--10).\[[@ref17]\] Tingling sensation, hyperesthesia, numbness, hot/cold sensation and burning sensation were measured by Likert scale (grade scores 0--2).\[[@ref18]\]

### Laboratory parameters {#sec3-3}

Laboratory assessment in terms of fasting and PPBS at 1-month interval and glycosylated Hb% (HbA1c %) before and after 3 months treatment were done.

Statistical analysis {#sec2-7}
--------------------

At the end of trial period, the data were analyzed on SPSS software version-16. (SPSS Inc. Released 2007. SPSS for Windows, Version 16.0. Chicago, SPSS Inc.).

Observation and Results {#sec1-3}
=======================

The observations made in this study are displayed in Tables [1](#T1){ref-type="table"}--[4](#T4){ref-type="table"}.

###### 

Symptom grade score shift index indicating overall symptomatic improvement
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###### 

The pattern of changes in blood sugar (F, PP), HbA1c before and after treatment
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###### 

The pattern of changes in, *Agni* and *Ojas* scores before and after treatment in different groups
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###### 

Pattern of percentage fall in fasting and PPBS after treatment in different trial groups
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Clinical symptoms of diabetes mellitus {#sec2-8}
--------------------------------------

Therapeutically it was observed that the trial treatment could produce statistically significant favorable shift of grade scores (*P* \< 0.01) in most of the symptoms (polyuria, polyphagia, polydipsia, weight loss, weakness, loss of libido, joint pains etc.) associated with DMs in group A, B and C. While comparing the symptoms between the groups, the trial response were statistically significant (*P* \< 0.01) in all the Groups in follow-up-3, except in joints pain and loss of libido (*P* \> 0.05). It was also observed that clinically the patients of Group A improved better than other groups \[[Table 1](#T1){ref-type="table"}\].

Clinical symptoms of diabetic neuropathy {#sec2-9}
----------------------------------------

Clinically it was observed that the shift of grades of tingling sensation within the group comparison in different trial groups was statistically not significant. Similar was the trend in the case of hyperesthesia, numbness and hot/cold sensation. Thus, the 3 months treatment with the trial drugs did not produce any neurological impact.

Fasting blood sugar {#sec2-10}
-------------------

The initial mean and standard deviation (SD) FBS for Group-A was 139.58 ± 34.01, after 3 months of treatment it reduced to 112.39 ± 32.75. The improvement was statistically significant (*P* \< 0.001). In Group-B, the initial mean and SD was144.74 ± 31.80, after 3 months of treatment it reduced to 131.81 ± 28.09. The improvement in blood sugar fasting was statistically significant (*P* \< 0.001). In Group-C, the initial mean and SD was 144.80 ± 60.08 after 3 months of treatment, it reduced to 113.49 ± 17.25. The improvement in blood sugar fasting was statistically significant (*P* \< 0.001). The intergroup comparison of FBS changes was statistically not significant (*P* \> 0.05) in Group A versus Group-C and Group-B versus Group-C.

Postprandial blood sugar {#sec2-11}
------------------------

The initial mean and SD of PPBS for Group-A was 244.36 ± 52.19, after 3 months of treatment it reduced to 185.63 ± 48.28. The improvement was statistically significant (*P* \< 0.001). In Group-B, the initial mean and SD was 258.66 ± 53.33, after 3 months of treatment it reduced to196.03 ± 40.61. The improvement in PPBS was statistically significant (*P* \< 0.00). In Group-C, the initial mean and SD was 207.79 ± 73.02 after 3 months of treatment, it reduced to 155.20 ± 19.87. The improvement in PPBS was statistically significant (*P* \< 0.001). The intergroup comparison there was no statistically significant (*P* \> 0.05) change in PPBS in Group-A versus Group-C and Group-B versus Group-C \[Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}\].

Glycosylated Hb {#sec2-12}
---------------

The initial mean and SD of HbA1c for Group-A was 8.17 ± 1.58, after 3 months of treatment it reduced to 7.76 ± 1.48. The improvement was statistically highly significant (*P* \< 0.001). In Group-B the initial mean and SD was 8.11 ± 1.38, after 3 months of treatment it reduced to 7.84 ± 1.25. The improvement in glycosylated Hb was statistically not significant (*P* \> 0.05). In Group-C, the initial mean and SD was 8.09 ± 1.48, after 3 months of treatment, it increased to 8.19 ± 1.50 and the change in HbA1c as statistically not significant (*P* \> 0.05).

While comparing in different groups there was statistically significant (*P* \< 0.05) change in HbA1c in Group-A versus Group-C. The change in HbA1c was statistically not significant (*P* \> 0.05) in Group-B versus Group-C \[[Table 2](#T2){ref-type="table"}\].

*Ojas* status scores {#sec2-13}
--------------------

The initial mean and SD of negative Ojas status score for Group-A was 7.09 ± 5.82, after 3 months of treatment it reduced to 2.76 ± 3.42. The improvement was statistically significant (*P* \< 0.001). In Group-B the initial mean and SD was 6.96 ± 6.83, after 3 months of treatment it reduced to 3.17 ± 4.22. The improvement in *Ojas* status score was statistically significant (*P* \< 0.001). In Group-C, the initial mean and SD was 5.57 ± 5.05, after 3 months of treatment, it reduced to 4.64 ± 4.82. The improvement in Ojas status score was statistically significant (*P* \< 0.001). Maximum improvement was seen in Group-A (*Mamajjaka* treated), then in Group-B (*Silajatu* treated) whereas in Group-C minimal change was seen. The intergroup comparison showed. Statistically significant change in Ojas status in Group-A versus Group-C (*P* \< 0.001) and Group-B versus Group-C (*P* \< 0.001) \[[Table 3](#T3){ref-type="table"}\].

*Agni* status scores {#sec2-14}
--------------------

The initial mean and SD of *Agni* status score for Group-A was 4.94 ± 3.27, after 3 months of treatment it reduced to 0.55 ± 0.62. The change was statistically significant (*P* \< 0.001)). In Group-B the initial mean and SD was 4.61 ± 4.36, after 3 months of treatment it reduced to 1.09 ± 1.44. The change in *Agni* status scores was statistically significant (*P* \< 0.001). In Group-C the initial mean and SD was 5.11 ± 3.47, after 3 months of treatment, it reduced to 3.39 ± 2.33. The change in *Agni* status scores was statistically significant (*P* \< 0.001). While comparing in different groups there is statistically significant change in *Agni* status in Group-A versus Group-C (*P* \< 0.001) and Group-B versus Group-C (*P* \< 0.02). Maximum improvement was seen in Group-A (*Mamajjaka* treated) then in Group-B (*Silajatu* treated) while in Group-C minimal change was seen \[[Table 3](#T3){ref-type="table"}\].

Correlation between *Ojas* and *Agni* status {#sec2-15}
--------------------------------------------

To measure the degree of linear relationship between *Ojas* and *Agni*, HbA1c and *Ojas*, HbA1c and *Agni* coefficient of correlation was determined. Correlation between *Ojas* and *Agni* was found positive and statistically significant at before and after treatment points. Correlation between HbA1c and *Ojas* was positive and lower but not statistically significant. Whereas correlation between HbA1c and *Agni* was negative and smaller and was not statistically significant. The negative value of this correlation shows that HbA1c and *Agni* are inversely related, that is, if one increases the other decreases and vice versa. The trends show that *Ojas* and *Agni* status correspond each other. HbA1c and *Ojas* status also influence each other. On the other hand HbA1c shows declining trend with improving *Agni* status \[[Table 5](#T5){ref-type="table"}\].

###### 

The correlation between the following variables

![](AYU-35-404-g005)

Discussion {#sec1-4}
==========

Diabetes mellitus is a disease known since the beginning of human civilization.\[[@ref19]\] Now it is the fifth leading cause of death in most developed countries and epidemic in many developing nations. The recent years have shown a significantly rising trend in the incidence of this disease all over the world especially in India. The Ayurvedic scholars since antiquity had the knowledge of *Madhumeha*, a disease synonymous with DM. Ayurveda considers diabetes as *Kaphaja* disease in which *Medas* (adipose factor) and *Ojas* (bio-strength cum immune strength) have been described as the main factors, which are affected in this disease. *Agni* (GI and cellular biofire) and *Ama*, that is, autotoxins; play a major role in disease diathesis and complications. These ancient observations are outstanding information regarding the nature of the disease. It is now well-known that DM results due to the metabolic derangement. Similarly, it is being now gradually conceived that there is a strong evidence of immune disorder and immunodeficiency in all diabetics and its related complications. Possibly, because of such morbid factors, the propounders of Ayurveda considered *Ojas* as an important *Dusya* (morbid factor) of *Madhumeha*, hence it is also termed as *Ojomeha*. *Medas* or the bodily lipids have strong association with DM and obesity, which may lead to a variety of other disorders.\[[@ref20][@ref21][@ref22]\] *Medas* with or without *Ama* is predicted to play a major role in the development of DM and its complications.

Conventional modern medicine is not always successful to control diabetes in all cases. Insulin is not always indicated due to the development of insulin resistance and generation of Insulin antagonists in the body, whereas the oral hypoglycemic drugs are found to be of limited use in many cases due to the major side-effects. Therefore, search for better remedies from Ayurvedic resources continues. The present study identifies a treatment strategy that not only corrects the metabolic derangements, but also helps in maintaining the *Agni* and *Ojas* status, that is, metabolic stability and immune strength in diabetic patients.

This study is based on investigations of 95 diagnosed cases of *Madhumeha* (DM-2), out of which 11 patients dropped out mostly because of change of place and only 84 patients could be studied under clinical trial of the two selected drugs along with a group of patients under conventional treatment for comparative purpose. In this study, *Mamajjaka* shows better results as compared to other groups. It is suggested that a combined treatment of DM with *Mamajjaka* and *Silajatu* could give still better results. *Silajatu*\[[@ref23]\] being a *Naimittika Rasayana* and *Mamajjaka*\[[@ref24][@ref25]\] being a therapeutic agent for this purpose could jointly form the full treatment modality for DM.

This study also suggests that the selected drugs help in preventing or delaying the complications in DM. The selected *Rasayana* drugs (*Silajatu* and *Mamajjaka*) by virtue of their *Rasayana* properties act at the level of *Agni*, *Srotasa* and *Rasa*, providing nourishment to the *Sapta Dhatu* \[[Table 5](#T5){ref-type="table"}\].\[[@ref26][@ref27]\]

The *Mamajjaka* treated patients have shown better percentage of fall in FBS (19.47%), in comparison to *Silajatu* treated patients (8.93%) while in case of PPBS the percentage of fall was almost equal in both the groups, that is, 24.03%, but the patients on conventional treatment showed more or less equal percentage of fall in both fasting and PPBS level. The special pattern of blood sugar response to *Silajatu* treatment (in relation to fasting and PP) deserves special consideration \[[Table 4](#T4){ref-type="table"}\].

Clinically, it was also observed that *Mamajjaka* treated patients showed a noticeable response in overall neurological symptoms. *Silajatu* treated patients showed significant and modern medicine treated patients showed an insignificant response in neurological symptoms in intergroup comparison.

The probable mode of action of the trial drugs in terms of conventional bio-sciences, cannot be explained at this stage. This study is largely an efficacy-validating investigation. It is not a mechanism testing study. *Silajatu* has been described as *Naimittika Rasayana* for *Prameha* by *Susruta* and *Dalhana* and *Mamajjaka* is in practice and being used by many Ayurveda physicians in India.

Conclusion {#sec1-5}
==========

The present clinical study shows that the selected *Rasayana* drugs may help to control blood sugar levels in mild to moderate diabetic patients and may retard the complications of DM. However, further longitudinal studies are warranted to explore the mode of action of these drugs in preventing neurological complications of DM. Although it is difficult to presume the possible mechanism of action of these drugs at this stage of study, but the authors are inclined to suggest that in view of their *Naimittika Rasayana* impact these drugs are likely to promote insulin production. Beside this, these drugs have capacity to improve overall health status of diabetic subjects. It was also observed that these *Rasayana* remedies not only correct the hyperglycemic episodes, but also produce their effect by enhancing the *Agni* and *Ojas* status in these patients, meaning thereby an improved metabolic and immune status. The *Rasayana* drugs used in this study seem to be safe, because no side-effects were noted in trial period in the present study.
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